Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Argus Lowers its Price Target on Becton, Dickinson and Company (BDX) to $180 from $230

AI-generated analysis

πŸ“‰ Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180 while maintaining a Buy rating.

πŸ”„ The downgrade cites the company's transition toward a pure-play medtech model following the spin-off of its Biosciences and Diagnostics Solutions business.

πŸ“Š BDX currently trades at approximately 11.5 times forward earnings, which is below the 20.4 times average for its MedTech coverage universe.

βœ… On March 23, 2026, the company received FDA 510(k) clearance for Surgiphor 1000mL, a new antimicrobial irrigation system for powered lavage.

πŸ’° Becton, Dickinson and Company reported Q1 adjusted EPS of $2.91 against a consensus estimate of $2.81 on revenue of $5.3B versus $5.15B expected.

πŸš€ CEO Tom Polen stated results reflected stronger-than-expected performance driven by execution and growth across key markets.

πŸ”„ Management confirmed the company is fully pivoting to New BD with a focus on innovation, productivity, and long-term growth.

🏭 Becton, Dickinson and Company develops and sells medical devices, laboratory equipment, and diagnostic products globally.

⚠️ The article notes that while acknowledging risk and potential in BDX as an investment, some conviction lies in AI stocks holding greater promise for higher returns.

πŸ’‘ The article references a report about a cheapest AI stock with alleged 10,000% upside potential, suggesting a comparison to BDX.

Bullish Signals
  • Argus maintained a 'Buy' rating on Becton, Dickinson and Company (BDX) despite lowering the price target, citing the company's successful transition toward a pure-play medtech model following its strategic spin-offs.
  • The stock trades at 11.5 times forward earnings, which is significantly below the 20.4 times average for its MedTech coverage universe, suggesting it may be undervalued relative to peers.
  • BDX recently announced FDA 510(k) clearance for Surgiphor 1000mL, marking the first of its kind antimicrobial irrigation system designed to improve surgical efficiency and safety.
  • First-quarter results exceeded analyst expectations with adjusted EPS of $2.91 versus a consensus estimate of $2.81, driven by stronger-than-expected performance across key markets.
  • The company reported revenue of $5.3 billion, surpassing the $5.15 billion expected, demonstrating robust operational execution and growth in its portfolio.
Risk Factors
  • Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180, a significant reduction of $50 per share.
  • Analysts view AI stocks as having greater promise for delivering higher returns in a shorter time frame than BDX, suggesting inferior growth potential relative to competitors.
  • The stock is considered undervalued at only 11.5 times forward earnings compared to the 20.4x average for its MedTech coverage universe, which may limit upside despite perceived undervaluation claims.
  • Argus cited a transition toward a pure-play medtech model following a spin-off of its Biosciences and Diagnostics Solutions business, indicating ongoing structural disruption and integration risks.
Full Analysis
Argus lowered its price target on Becton, Dickinson and Company (NYSE:BDX) from $230 to $180 on March 23, 2026, while maintaining a Buy rating. The firm cited the company's strategic transition toward a pure-play medical technology model following the spin-off of its Biosciences and Diagnostics Solutions business as a key factor in this adjustment. According to Argus, BDX currently trades at approximately 11.5 times forward earnings, which is significantly below the 20.4 times average for its MedTech coverage universe. Despite the downward revision to the price target, the company maintains its positive stance, acknowledging the risks and potential associated with investing in BDX. In recent financial developments, Becton Dickinson announced it received FDA 510(k) clearance on March 23, 2026, for Surgiphor 1000mL, a system described as the first 1000 mL antimicrobial irrigation system designed for powered lavage intended to improve surgical efficiency and safety. Earlier in the month, the company reported Q1 adjusted earnings per share (EPS) of $2.91, surpassing the consensus estimate of $2.81 on revenue of $5.3 billion compared to the expected $5.15 billion. CEO Tom Polen noted that these results reflected stronger-than-expected performance driven by execution and growth across key markets, emphasizing that the company is fully pivoting toward "New BD" with a focus on innovation, productivity, and long-term growth as part of its portfolio changes. The article further highlights that Becton Dickinson develops and sells medical devices, laboratory equipment, and diagnostic products globally. It concludes with promotional content for an investment platform claiming certain AI stocks offer higher returns with 10,000% upside potential and provides a list of other recent Wall Street bullish moves on defense and aerospace companies such as L3Harris Technologies, Lockheed Martin, Northrop Grumman, General Dynamics, and Rocket Lab. A disclosure states there is no conflict of interest or affiliate relationship disclosed within the content regarding BDX specifically.